This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Dynavax Technologies Corporation
Drug Names(s): ISS-1018
Description: Dynavax Technologies is developing short, immunostimulatory DNA sequences (ISS). 1018 ISS is a CpG oligodeoxynucleotides (CpG-ODNs). CpG-ODNs affect innate and adaptive immune responses, including antigen presentation, costimulatory molecule expression, dendritic cell maturation, and induction of cytokines enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).
1018 ISS News
Pink Sheet FDA Performance Tracker: CBER Approvals
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: